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ABSTRACT The Roche cobas MTB and MTB-RIF/INH assays allow for detection
of Mycobacterium tuberculosis complex (MTBC) nucleic acid and rifampicin (RIF) and
isoniazid (INH) resistance-associated mutations in an automated, high-throughput
workflow. In this study, we evaluated the performance of these assays, employing
samples from settings of low and high tuberculosis (TB) burdens. A total of 325 frozen,
leftover respiratory samples collected from treatment-naive patients with presumptive
TB in Germany (n=280) and presumptive RIF-resistant TB in Sierra Leone (n=45) were
used in this study. cobas MTB results for detection of MTBC DNA from N-acetyl-L-cyste-
ine–sodium hydroxide (NALC–NaOH)-treated samples were compared to culture
results. Predictions of RIF and INH resistance by the cobas MTB-RIF/INH assay were
compared to a composite reference standard (phenotypic drug susceptibility testing
and line probe assay). Whole-genome sequencing was used to resolve discordances.
The overall sensitivity of cobas MTB for detection of MTBC DNA in culture-positive
samples (n=102) was 89.2% (95% confidence interval [CI], 81.7 to 93.9%). The specific-
ity of cobas MTB was 98.6% (95% CI, 96.1 to 99.5%). Sensitivity and specificity for
detection of RIF and INH resistance were 88.4% (95% CI, 75.5 to 94.9%) and 97.6%
(95% CI, 87.4 to 99.6%) and 76.6% (95% CI, 62.8 to 86.4%) and 100.0% (95% CI, 90.8
to 100.0%), respectively. Discordant results for RIF and INH resistance were mainly due
to uncommon mutations in samples from Sierra Leone that were not covered by the
cobas MTB-RIF/INH assay. In conclusion, cobas MTB and MTB-RIF/INH assays provide
accurate detection of MTBC DNA and resistance-associated mutations in respiratory
samples. The influence of regional variations in the prevalence of resistance-conferring
mutations requires further investigation.
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In 2019, there were an estimated 1.2 million deaths from tuberculosis (TB) amongHIV-negative people and 10 million new TB cases worldwide (1). Approximately 4%
of these cases were caused by multidrug-resistant (MDR) strains of Mycobacterium tu-
berculosis complex (MTBC), which are characterized by resistance to at least the two
most effective first-line drugs, isoniazid (INH) and rifampicin (RIF) (1–3). Treatment suc-
cess rates are lower for MDR-TB than for drug-susceptible TB (57% and 85%, respec-
tively) (1), clearly falling short of the World Health Organization (WHO)-devised End TB
Strategy target of a $90% treatment success rate by 2025 (4). Additionally, INH- and
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RIF-monoresistant forms of TB are also associated with poorer patient outcomes (5, 6)
and are highly prevalent in some high-burden settings (7–9). For example, in South
Africa (2012 to 2014), the prevalence of INH-monoresistant TB was .5% in all provin-
ces (9). The prevalence of new RIF-resistant TB cases (3.4%) almost doubled compared
with 2001-2002 data (1.8%), while the prevalence of MDR-TB remained stable (2.8%
versus 2.9%) (9).
Consequently, the End TB Strategy has renewed the call for universal drug suscepti-
bility testing to be available for patients with confirmed TB (1, 4). However, conven-
tional phenotypic drug susceptibility testing (pDST) is time-consuming and complex,
involving culturing of clinical samples in a biosafety level 3 facility, which is not always
available in high-burden settings. In order to appropriately identify and treat MDR- as
well as INH- and RIF-monoresistant TB, rapid detection of resistance-conferring muta-
tions for both drugs is required (10). Nucleic acid amplification tests (NAATs) are useful
alternative tools for the detection of MTBC and drug resistance markers directly from
clinical samples (11). Testing for RIF resistance-associated mutations in the rpoB gene
and INH resistance-associated mutations in the katG gene and fabG1-inhA promoter
region offers the possibility to accelerate identification of drug resistance compared to
pDST (2, 11). However, due to the type and frequency of these mutations varying
across geographic regions and their disparate impacts on phenotypic resistance pro-
files, it is important to validate the clinical application of NAATs in various settings (9,
12–14).
The Roche cobas MTB and MTB-RIF/INH assays offer a high-throughput NAAT plat-
form for direct detection of MTBC DNA, and RIF and INH resistance-associated muta-
tions (15) from inactivated human respiratory samples, including raw and processed
sputum and bronchoalveolar lavage (BAL) fluid. MTBC DNA-positive samples are subse-
quently tested for resistance-associated mutations, which allows for diagnosis of RIF or
INH monoresistance as well as MDR-TB. Limited data are available for the performance
of the cobas MTB and MTB-RIF/INH assays compared to culture and other commercially
available NAATs (16, 17).
This study aimed to evaluate the sensitivity and specificity of the cobas MTB and
MTB-RIF/INH system in a reference laboratory which receives samples from settings of
low (Germany; notification rate, 5.8/100,000 population) and high (Sierra Leone; notifi-
cation rate, 295/100,000) TB burdens (18).
MATERIALS ANDMETHODS
Study design and ethics. This was a single-center, retrospective evaluation using remnant samples
submitted to the German National Reference Center for Mycobacteria for testing, until the target num-
ber of samples needed to meet the study objectives was obtained (60 MTBC culture-positive and 150
MTBC culture-negative samples). All samples were anonymized prior to inclusion. The study was con-
ducted in compliance with the International Conference on Harmonisation Good Clinical Practice
Guideline and local regulations. The study protocol was approved by the relevant institutional review
board prior to initiation.
Samples. Remnant frozen N-acetyl-L-cysteine–sodium hydroxide (NALC–NaOH)-treated sputum sam-
ples and BAL fluid sediments of more than 500ml obtained from individuals suspected of having TB
were used in this study. Samples from Sierra Leone that locally screened MTBC positive and RIF resistant
by Xpert MTB/RIF (Cepheid, Sunnyvale, CA) were sent to Germany for confirmation by culture, pDST, and
molecular DST (mDST) as required. All samples were taken from adults aged .18 years within 2 days of
patients starting TB treatment. Samples from patients who were already on treatment were excluded.
Cross-reactivity with nontuberculous mycobacteria (NTM) was explored using remnants of 18 micro-
scopically positive sputa obtained in Germany that grew Mycobacterium avium complex, Mycobacterium
kansasii, or Mycobacterium abscessus.
Testing. Testing was performed at the National Reference Center for Mycobacteria in Borstel,
Germany, on a cobas 6800 system using the cobas MTB assay with the cobas MTB positive control,
buffer negative control, and microbial inactivation solution (Roche, Rotkreuz, Switzerland). All cobas
MTB PCR-positive samples were subsequently investigated for RIF and INH resistance using the cobas
MTB-RIF/INH assay. Analytical data obtained during routine diagnostic workups were collected from the
electronic laboratory management system. These data included results for fluorescence smear micros-
copy, growth on solid (one Löwenstein-Jensen and one Stonebrink slant per sample) and liquid (Bactec
MGIT 960; Becton, Dickinson, Franklin Lakes, NJ) culture media, pDST results for INH and RIF at the WHO-
recommended critical concentrations (CC) of 0.1mg/liter and 1.0mg/liter, respectively (19), and results
for the GenoType MTBDRplus (Hain Lifescience, Nehren, Germany) line probe assay (LPA) where
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applicable. Results of the Xpert MTB/RIF assay were available for a subset of 128 samples. Selected sam-
ples, in particular the discordant samples, were also tested by the Xpert MTB/RIF Ultra assay (Cepheid,
Sunnyvale, CA).
Whole-genome sequencing. Whole-genome sequencing (WGS) was performed with Illumina tech-
nology employing the NextSeq500 and Nextera XT DNA library preparations according to the manufac-
turer’s instructions (Illumina, San Diego, CA), and the MTBseq pipeline was used for data analysis, as
described previously (20). Briefly, raw reads were mapped to the M. tuberculosis H37Rv genome
(GenBank accession number NC_000962.3), and variants (single nucleotide polymorphisms and small
insertions and deletions) with a minimum coverage of four reads in both forward and reverse orienta-
tions, at least four reads calling the variant with a Phred score of $20, and a minimum variant frequency
of 75% were extracted.
Genes and upstream regions implicated in resistance to INH (katG, fabG1, inhA, inbR, mshA, mmaA3,
mshB, sigI, ndh, furA, mshC, kasA, mymA, nudC, nat, and Rv3083) and RIF (rpoB) were investigated for re-
sistance-associated mutations and interpretation of discordant results. The absence of sequencing reads
in the aforementioned genes was reported as large unspecified deletions. Previously identified muta-
tions in these genes that are not correlated with resistance but rather reflect phylogenetic variation
were not considered possible resistance determinants (21).
Analyses. cobas MTB results were compared to growth of MTBC bacteria in solid or liquid medium
as a reference. Smear-negative and smear-positive samples were analyzed separately. cobas MTB data
were compared to Xpert MTB/RIF or Xpert MTB/RIF Ultra results where available. For prediction of resist-
ance to INH or RIF, cobas MTB-INH/RIF results were compared to a composite reference standard (CRS)
comprising routine pDST (MGIT 960) and mDST by LPA. Samples were flagged resistant as per the CRS if
growth occurred at the CC for INH or RIF or in case of detection of a “borderline” mutation associated
with elevated RIF MICs below the CC. WGS was used to resolve discordances between the cobas MTB-
RIF/INH and CRS results. Statistical analyses were performed using SAS/STAT software.
RESULTS
Samples. In total, 325 sputum samples from treatment-naive patients with sus-
pected TB from Germany (n=280 [86.0%]) and Sierra Leone (n=45 [14.0%]) were
investigated (1 sample per patient [Fig. 1]). Of patients from Germany, 63.6% were
male (n=178), 28.2% were female (n=79), and the sex of 8.2% (n=23) was unknown,
with a median age for all patients of 52 years (interquartile range [IQR], 33 to 70). Of
patients from Sierra Leone, 71.1% (n=32) were male and 28.9% (n=13) were female,
with a median age of 30 years (IQR, 21 to 42).
FIG 1 Sample flow and analytical procedures. TB, tuberculosis; NALC–NaOH, N-acetyl-L-cysteine–sodium
hydroxide; LJ, Löwenstein-Jensen medium; MGIT, mycobacterial growth indicator tube; pDST, phenotypic drug
susceptibility testing; mDST, molecular drug susceptibility testing; LPA, line probe assay; RIF, rifampicin; INH,
isoniazid.
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Performance of the cobas MTB assay. The overall sensitivity of the cobas MTB assay
for detection of MTBC in culture-positive samples was 89.2% (95% confidence interval
[CI], 81.7 to 93.9%) (Table 1). As expected, for smear-positive, culture-positive samples,
cobas MTB demonstrated a higher sensitivity (98.7%; 95% CI, 92.8 to 99.8%) than for
smear-negative, culture-positive samples (63.0%; 95% CI, 44.2 to 78.5% [Table 1]).
With regard to the geographic origin of the samples, the cobas MTB assay correctly
detected TB in all of the culture-positive samples from Sierra Leone, which were mostly
smear-positive (42/45 samples [93.3%] [Table 1]). Among the 57 MTBC culture-positive
samples from Germany, 33 (57.9%) were smear-positive. Consequently, the sensitivity
of the cobas MTB assay for detection of MTBC DNA was lower in this sample subset
(80.7%; 95% CI, 68.7 to 88.9% [Table 1]).
Since all samples from Sierra Leone were MTBC culture-positive, specificity was
investigated based on samples from Germany alone (98.6%; 95% CI, 96.1 to 99.5%). In
total, 3/222 MTBC culture-negative samples were classified as positive by the cobas
MTB assay. Of those, 2/3 samples were both smear- and culture-negative and 1 grew
Mycobacterium chimaera but not MTBC. With regard to the latter, repetition of cobas
MTB from the positive MGIT 960 culture gave a negative result; no leftover primary ma-
terial was available for repeat testing. Information on a history of TB that could explain
the positive PCR results was not available.
Cross-reactivity with nontuberculous mycobacteria (NTM) was investigated using
18 microscopically positive sputa that grew M. avium complex, M. kansasii, or M.
abscessus (Table 1). cobas MTB was negative in 17/18 NTM culture-positive samples
(94.4%; 95% CI, 72.7 to 99.9%), with the one falsely positive cobas MTB result corre-
sponding to a sample that grew M. chimaera as outlined above.
A comparative analysis between cobas MTB and Xpert MTB/RIF based on 128 sam-
ples (smear-positive/MTBC culture-positive, n=60; smear-negative/MTBC culture-posi-
tive, n=15; smear-positive/MTBC culture-negative but M. kansasii culture-positive,
n=1; and smear-negative/MTBC culture-negative, n=52) showed 99.2% (95% CI, 95.7
to 99.9%) overall agreement for detection of MTBC DNA (see Table S1 in the supple-
mental material).
Detection of rifampicin and isoniazid resistance. Both RIF and INH resistances as
per the CRS were more frequent among samples from Sierra Leone than among sam-
ples from Germany and more frequent in smear-positive than in smear-negative sam-
ples (Table S2). Overall, cobas MTB-RIF/INH demonstrated a sensitivity of 88.4% (95%
CI, 75.5 to 94.9%; 38/43 samples) for detection of RIF resistance and a sensitivity of
76.6% (95% CI, 62.8 to 86.4%; 36/47 samples) for detection of INH resistance.
Specificities were 97.6% (95% CI, 87.4 to 99.6%; 40/41 samples) for RIF and 100.0%
(95% CI, 90.8 to 100.0%; 38/38 samples) for INH (Table 2).
MTBC isolates that displayed either INH (n=9) or RIF (n=5) resistance by the CRS
but were not identified by cobas MTB-RIF/INH (15.4% of all results generated by cobas
MTB-RIF/INH) were further analyzed using WGS (Table 3). For INH, all samples with dis-
cordant results originated from Sierra Leone. Resistance was associated with
TABLE 1 Diagnostic performance of the cobas MTB assay for identification ofMycobacterium tuberculosis complex nucleic acid from primary
samplesa
Sample source
No. of samples/total (% [95% CI])
Sensitivity
SpecificitySmear-positive Smear-negative Pooled
Germany 32/33 (97.0 [84.7, 99.5]) 14/24 (58.3 [38.8, 75.5]) 46/57 (80.7 [68.7, 88.9]) 219/222b (98.6 [96.1, 99.5])
Sierra Leone 42/42 (100.0 [91.6, 100.0]) 3/3 (100.0 [43.9, 100.0]) 45/45 (100.0 [92.1, 100.0]) NAc
All samples 74/75 (98.7 [92.8, 99.8]) 17/27 (63.0 [44.2, 78.5]) 91/102 (89.2 [81.7, 93.9]) 219/222 (98.6 [96.1, 99.5])
aCulture was used as a reference standard. CI, confidence interval.
bA total of 18/222 (8.1%) of the investigatedMycobacterium tuberculosis complex (MTBC)-negative samples grew nontuberculous mycobacteria (Mycobacterium avium
complex, n= 9;Mycobacterium kansasii, n=6; andMycobacterium abscessus, n= 3).
cOnly MTBC culture-positive samples from Sierra Leone were analyzed. NA, not applicable.
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uncommon mutations in katG such as M105I, W397C, or deletion at 792G (del792G),
mostly in combination with mutations in other genes associated with INH resistance,
such as fabG1, mshB, and nudC (Table 3). For RIF, three discordant samples originated
from Sierra Leone and two from Germany. Of the five discordant results, two had entire
codon deletions in rpoB (at position 517 or 518) and two had point mutations resulting
in rpoB S531F or rpoB Q513E (Table 3). The MTBC isolate grown from the fifth sample
had the commonly observed S531L mutation in rpoB. Repeat testing was not possible
due to the limited volume of the primary sample. Repeat testing by cobas MTB-RIF/INH
from the corresponding MTBC culture isolate correctly identified the isolate as RIF re-
sistant. Of note, the S531L mutation was correctly detected in 21 unrelated samples.
Excluding this sample, the sensitivity of cobas MTB-RIF/INH for determining RIF resist-
ance would have increased to 90.5% (n=38/42).
DISCUSSION
Our study demonstrates that the cobas MTB assay meets the minimal performance
characteristics stated in the WHO target product profile for a same-day diagnostic test
detecting pulmonary TB as an alternative to smear microscopy, which is a sensitivity of
.80% (smear-negative samples, .60%; smear-positive samples, 99%) and a specificity
of .98% compared with culture (22). We observed that the overall sensitivity of cobas
MTB (89.2%; 95% CI, 81.7 to 93.9%) was lower than in a study by Scott et al., who
reported an overall sensitivity of 94.7% (95% CI, 88.1 to 98.3%) using decontaminated
sputum sediments from individuals with presumptive or confirmed TB in South Africa
(16). However, the proportion of smear-negative, culture-positive samples in our study
was significantly larger (26.5% versus 7%) (16). In addition, Scott et al. reported a sensi-
tivity of 81.8% (95% CI, 59.7 to 94.8%) for cobas MTB in smear-negative samples, com-
pared to 63.0% (95% CI, 44.2 to 78.5%) in this study, which is likely a reflection of a
lower bacterial burden even among smear-negative patients in Germany than among
smear-negative patients in South Africa (16).
Both the sensitivity and specificity of the cobas MTB assay for detection of MTBC
DNA in clinical samples were comparable to or superior to those of five other platforms
mentioned in the WHO consolidated guidelines on tuberculosis (11). Therein, perform-
ance data were reported for Xpert MTB/RIF, Xpert MTB/RIF Ultra, Truenat MTB and
Truenat MTB plus (Molbio Diagnostics, India), and a loop-mediated isothermal amplifi-
cation assay, with overall sensitivities and specificities ranging from 73 to 90% and 96
to 98%, respectively (11). These findings indicate that the current approaches for
detection of MTBC nucleic acid in clinical samples have matured to a point where sig-
nificant further improvement, particularly regarding sensitivity in microscopically nega-
tive samples, will likely depend on new technological advances. The excellent overall
agreement between cobas MTB and Xpert MTB/RIF found in this study further corrobo-
rates this observation (Table S1).
Overall, the cobas MTB-RIF/INH assay performed well in detecting mutations confer-
ring resistance to INH and RIF (Table 2). For INH, all discordant results could be
explained by mutations at uncommon positions within katG and within other genes
associated with INH resistance that had not been defined as intended target mutations
of the cobas MTB-RIF/INH assay (Table 3). Notably, these mutations were also missed
TABLE 2 Identification of rifampicin and isoniazid resistance-associated mutations fromMycobacterium tuberculosis complex DNA-positive
samples by the cobas MTB-RIF/INH assaya
Drug
No. of samples/total (% [95% CI])
Sensitivity
SpecificitySmear-positive Smear-negative Pooled
Rifampicin 36/40 (90.0 [76.9, 96.0]) 2/3 (66.7 [20.8, 93.9]) 38/43 (88.4 [75.5, 94.9]) 40/41 (97.6 [87.4, 99.6])
Isoniazid 32/42 (76.2 [61.5, 86.5]) 4/5 (80.0 [37.6, 96.4]) 36/47 (76.6 [62.8, 86.4]) 38/38 (100.0 [90.8, 100.0])
aA combination of phenotypic and molecular (line probe assays) drug susceptibility testing performed from cultures was used as a composite reference standard. CI,
confidence interval.
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by LPA (Table 3). For RIF, codon deletions or point mutations that had also not been
included as intended target mutations explained four of the five discordant results
(Table 3). All four isolates tested resistant to RIF and INH in pDST (Table 3). As a conse-
quence, two of the corresponding patients (18001889, katG S315T and rpoB S531F;
18002314, katG S315T and rpoB Q513E [Table 3]) would have been diagnosed with pre-
sumptively INH-monoresistant TB, while the other two (18000119, katG del792G and
rpoB del517; 18001933, katG W397C, mshB S219S, nudC L293L, and rpoB del518 [Table
3]) would have been diagnosed with presumptively RIF- and INH-susceptible TB based
on the cobas MTB-RIF/INH results alone until pDST results became available. In con-
trast, employing LPA would have led to RIF resistance being inferred from missing rpoB
wild-type bands in all four cases. These results would have likely triggered (i) DNA
sequencing of rpoB to rule out silent mutations (which is dependent on sample quan-
tity and equipment availability) and (ii) initiation of treatment for RIF-resistant/MDR-TB
based on the assumption that any nonsilent mutation observed in the 81-bp hot spot
region of rpoB, as well as some mutations outside this region, is clinically relevant at
the current standard dose of RIF. With Xpert MTB/RIF Ultra, all four samples gave a RIF-
resistant result (Table 3). As with LPA, this would have likely triggered follow-up testing
and initiation of a regimen for RIF-resistant/MDR-TB.
Our findings demonstrate the geographically heterogeneous distribution of uncom-
mon mutations conferring resistance to the most important first-line anti-TB drugs
(23). In light of previous reports from Eswatini and South Africa demonstrating the
spread of an MDR-MTBC outbreak strain carrying an I491F mutation in rpoB which
remained undetected by Xpert MTB/RIF (24, 25), our observations highlight that similar
events can occur anywhere and anytime. In addition, this finding underlines the poten-
tial of nationwide, WGS-based drug resistance surveys to unveil MTBC clones that
escape the NAATs deployed for routine TB screening (24, 25). Recent work on genome-
based prediction of drug resistance and curation of MTBC mutation databases takes
into account the geographically heterogeneous prevalence of resistance-conferring
mutations (26–29). However, this also has some important implications for the design
and implementation of NAATs for detection of MTBC from primary samples. First,
developers of novel NAATs should consider the regional pathogen diversity found in
the intended target markets. Second, NAATs for prediction of RIF or INH resistance
should be quickly updated if major shifts in the molecular drug resistance landscape
are observed in specific regions or on a global level. Third, test performance character-
istics available from the literature should be related to the regional context prior to
implementation of a new NAAT for TB screening.
This study has several limitations. First, this was a retrospective study using limited
volumes of stored, frozen samples from only two countries and with limited clinical
metadata. Oversampling of MTBC-positive cases prevented the calculation of positive
predictive values. Moreover, for Sierra Leone, only samples that grew RIF-resistant
MTBC isolates were investigated, and these do not represent the large proportion of
TB patients in the country who suffer from fully susceptible TB. Also, assay specificity in
high-TB-burden settings will require further investigation. Lastly, the number of smear-
negative, culture-positive samples available to us was limited, resulting in relatively
large confidence intervals for the assay sensitivity in this sample subset. On the other
hand, the fact that we were able to investigate a comparably large number of RIF- and
INH-resistant samples with a broad range of mutations, and with full resolution of dis-
cordant results by WGS, represents a major strength of this study.
In conclusion, the cobas MTB and MTB-RIF/INH assays can serve as a high-through-
put diagnostic platform for diagnosis of drug-sensitive or drug-resistant TB, in particu-
lar as part of population-wide screening efforts to achieve the targets outlined by the
WHO End TB Strategy (4). Due to its size and throughput, the platform is particularly
suited for placement in core laboratories where it could be used in an integrated diag-
nostic setting, including additional testing for HIV and COVID-19. The cobas MTB-RIF/
INH assay could identify and differentiate both RIF- and INH-monoresistant TB from
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MDR-TB in the majority of the investigated samples, enabling tailored therapeutic
interventions based on current guidelines and recommendations. In addition to pub-
lished performance characteristics, cost, throughput, and the locally available logistic
infrastructure, the choice of a NAAT for MTBC screening should be informed by ge-
nome-based regional surveillance studies to assess whether the assay will cover clones
of local relevance.
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